STXS - Stereotaxis, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
3.0000
+0.0300 (+1.01%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.9700
Open3.0200
Bid0.6200 x 800
Ask3.5000 x 800
Day's Range2.9100 - 3.0300
52 Week Range1.7000 - 5.8200
Volume168,620
Avg. Volume296,622
Market Cap207.1M
Beta (5Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)-0.1000
Earnings DateMar 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Can You Imagine How Elated Stereotaxis's (NYSEMKT:STXS) Shareholders Feel About Its 314% Share Price Gain?
    Simply Wall St.

    Can You Imagine How Elated Stereotaxis's (NYSEMKT:STXS) Shareholders Feel About Its 314% Share Price Gain?

    Stereotaxis, Inc. (NYSEMKT:STXS) shareholders might understandably be very concerned that the share price has dropped...

  • Thomson Reuters StreetEvents

    Edited Transcript of STXS earnings conference call or presentation 10-Mar-20 2:00pm GMT

    Q4 2019 Stereotaxis Inc Earnings Call

  • GlobeNewswire

    Stereotaxis Reports 2019 Full Year Financial Results

    ST. LOUIS, March 10, 2020 -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial.

  • ACCESSWIRE

    Stereotaxis, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 10, 2020 / Stereotaxis, Inc. (NYSEAMERICAN:STXS) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 10, 2020 at 10:00 ...

  • GlobeNewswire

    Stereotaxis Earns FDA Clearance and Announces U.S. Launch of Genesis Robotic Magnetic Navigation System

    Stereotaxis (STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the Genesis RMN® System for the robotic navigation of magnetic ablation catheters to treat heart rhythm disorders. “Genesis is a leap forward in Robotic Magnetic Navigation technology,” said David Fischel, Chairman and CEO.

  • GlobeNewswire

    Stereotaxis to Present at Three Investor Conferences in March

    Stereotaxis (STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and CEO, will present at three investor conferences in March 2020. Mr. Fischel will present an overview of Stereotaxis business on Monday, March 2, 2020, 4:50 - 5:20 pm EST, will participate in a breakout session immediately afterwards, and will be available that day for one-on-one meetings. Mr. Fischel will present an overview of Stereotaxis business on Tuesday, March 17, 2020 from 4:30 - 5:00 pm EST, and will be available that day for one-on-one meetings.

  • GlobeNewswire

    Stereotaxis to Report Fourth Quarter and Full Year 2019 Financial Results on March 10, 2020

    ST. LOUIS, Feb. 26, 2020 -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it.

  • Does Stereotaxis, Inc.'s (NYSEMKT:STXS) CEO Pay Matter?
    Simply Wall St.

    Does Stereotaxis, Inc.'s (NYSEMKT:STXS) CEO Pay Matter?

    David Fischel became the CEO of Stereotaxis, Inc. (NYSEMKT:STXS) in 2017. First, this article will compare CEO...

  • GlobeNewswire

    Stereotaxis to Ring the Opening Bell® of the New York Stock Exchange

    Stereotaxis (STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that David Fischel, Chairman and CEO, will ring the Opening Bell® of the New York Stock Exchange on Tuesday, January 21, 2020 to celebrate Stereotaxis' positive impact on healthcare and recent listing on the exchange. In addition to television coverage of the ceremony, the New York Stock Exchange will live stream the Opening Bell ringing on its website: https://www.nyse.com/bell.

  • One Thing To Remember About The Stereotaxis, Inc. (NYSEMKT:STXS) Share Price
    Simply Wall St.

    One Thing To Remember About The Stereotaxis, Inc. (NYSEMKT:STXS) Share Price

    If you own shares in Stereotaxis, Inc. (NYSEMKT:STXS) then it's worth thinking about how it contributes to the...

  • Hedge Funds Have Never Been This Bullish On Stereotaxis Inc (STXS)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Stereotaxis Inc (STXS)

    Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]

  • GlobeNewswire

    First Patients Treated in New Robotic Arrhythmia Care Program at Overland Park Regional Medical Center

    Stereotaxis (STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that HCA Midwest Health—the largest healthcare system in the Kansas City region—has launched a new robotic arrhythmia care program based at Overland Park Regional Medical Center (OPRMC). Installation of the Stereotaxis Robotic Magnetic Navigation (RMN) System was recently completed, and the first patients have been successfully treated using the technology at Overland Park Regional Medical Center. Stereotaxis’ partnership with HCA Midwest Health brings new, leading-edge treatment options for patients who have a cardiac arrhythmia.

  • GlobeNewswire

    Stereotaxis CEO to Present at the 12th Annual LD Micro Main Event Investor Conference

    Stereotaxis (STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today its Chairman and Chief Executive Officer, David Fischel, will present at the 12th Annual LD Micro Main Event investor conference. The conference, held at the Luxe Sunset Bel Air Hotel, will feature 275 emerging growth companies and is expected to attract 1,500 attendees. Mr. Fischel will present an overview of Stereotaxis on Tuesday, December 10, 2019 at 8:00 a.m. PT, discussing the company’s technology, clinical value, recent innovations, and commercial growth strategy.

  • Thomson Reuters StreetEvents

    Edited Transcript of STXS earnings conference call or presentation 14-Nov-19 2:00pm GMT

    Q3 2019 Stereotaxis Inc Earnings Call

  • GlobeNewswire

    Stereotaxis CEO to Present at the 12th Annual BIOMEDevice San Jose Conference

    Stereotaxis (STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today its Chairman and Chief Executive Officer, David Fischel, will present at the 12th annual BIOMEDevice San Jose conference. BIOMEDevice San Jose is a two-day educational program focused on the expansion of digital technology in the field of healthcare, gathering top medical device innovators, experts, and physicians to discuss the role of digital medicine in revolutionizing the healthcare industry.

  • GlobeNewswire

    Stereotaxis Reports 2019 Third Quarter Financial Results

    ST. LOUIS, Nov. 14, 2019 -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial.

  • GlobeNewswire

    Stereotaxis and Catheter Precision Combine Robotic Navigation and Preoperative Arrhythmia Localization to Treat Cardiac Arrhythmias

    Stereotaxis (NYSE American: STXS) and Catheter Precision today announced the first patients have been successfully treated with the integration of Catheter Precision’s VIVO™ arrhythmia localization and Stereotaxis’ Robotic Magnetic Navigation technologies. VIVO uses information commonly collected prior to cardiac procedures to identify the source of dangerously rapid heartbeats.

  • Could Stereotaxis, Inc.'s (NYSEMKT:STXS) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Stereotaxis, Inc.'s (NYSEMKT:STXS) Investor Composition Influence The Stock Price?

    A look at the shareholders of Stereotaxis, Inc. (NYSEMKT:STXS) can tell us which group is most powerful. Insiders...

  • GlobeNewswire

    Stereotaxis to Report Third Quarter 2019 Financial Results on November 14, 2019

    ST. LOUIS, Nov. 06, 2019 -- Stereotaxis, Inc. (NYSE American: STXS) the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today.

  • GlobeNewswire

    Stereotaxis and inHEART Combine Robotic Precision and Advanced Preoperative 3D Mapping to Treat Cardiac Arrhythmias

    Stereotaxis (NYSE American: STXS) and inHEART today announced the first patients have been successfully treated with the integration of inHEART’s advanced preoperative mapping and Stereotaxis’ Robotic Magnetic Navigation technologies. The latest version of Stereotaxis software, recently cleared for use in Europe and by the FDA, utilizes a software interface that integrates inHEART’s maps, cleared for use in Europe, and allows physicians to utilize them to guide robotic cardiac ablation procedures.

  • GlobeNewswire

    Stereotaxis and ADAS 3D Combine Robotic Precision and Advanced Preoperative Substrate Mapping to Treat Cardiac Arrhythmias

    Stereotaxis (NYSE American: STXS) and ADAS 3D Medical SL today announced the first patients have been successfully treated with the integration of ADAS 3D’s advanced preoperative substrate mapping and Stereotaxis’ Robotic Magnetic Navigation technologies. ADAS 3D helps identify possible sources of dangerous irregular heartbeats and provides a map to guide physicians in delivering treatment. The software uses preoperative cardiac MRI to generate detailed three-dimensional cardiac models that identify arrhythmia substrate and characterize cardiac tissue.

  • This Hedge Fund Returns 22% Annually, Here Are Its Latest Picks
    Insider Monkey

    This Hedge Fund Returns 22% Annually, Here Are Its Latest Picks

    DAFNA Capital Management was founded in 1999 by Dr. Nathan Fischel, who is the fund’s CEO. Dr. Fischel is Pediatric Hematologist-Oncologist with a long career in medicine. He graduated from Technion School of Medicine in Israel and completed his residency at the Children’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston. He continued his […]

  • GlobeNewswire

    Stereotaxis Announces CFO Transition

    Stereotaxis (NYSE American: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that Kimberly Peery has been appointed Stereotaxis Chief Financial Officer, effective October 1, 2019. Martin Stammer, who has served as Chief Financial Officer since 2013, has accepted a position as the CFO of a large professional services firm headquartered in the St. Louis area and will resign from the Company, effective September 30, 2019. “I have really enjoyed my time at Stereotaxis and firmly believe in the future of the Company,” said Martin Stammer.

  • GlobeNewswire

    Stereotaxis Announces Uplisting to NYSE American

    Stereotaxis (STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that its common stock has been approved for listing on the NYSE American. The Company’s common stock will begin trading on the NYSE American exchange under its current symbol, “STXS,” at the open of trading on Sept. 6, 2019. The Company’s common stock will continue to trade on the OTCQX until the close of the market on Sept. 5, 2019.

  • Thomson Reuters StreetEvents

    Edited Transcript of STXS earnings conference call or presentation 8-Aug-19 1:00pm GMT

    Q2 2019 Stereotaxis Inc Earnings Call